Olmesartan Medoxomil/Hydrochloorthiazide Krka (Olmesartan Medoxomil, Hydrochlorothiazide)

Olmesartan medoxil, the active ingredient in Olmesartan Medoxomil/Hydrochloorthiazide Krka, is an angiotensin II receptor blocker presented as a tablet for oral use. It is used to manage high blood pressure, often in combination with a diuretic, and is prescribed for adults.

GNH USA supplies Olmesartan Medoxomil/Hydrochloorthiazide Krka as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals and pharmacies worldwide.

Olmesartan Medoxil/Hydrochlorothiazide is indicated for hypertension management, acting on the renin‑angiotensin‑aldosterone system and fluid balance. - Hypertension: lowers systolic and diastolic blood pressure to reduce cardiovascular risk. - Hypertension with fluid retention: provides additional blood‑pressure reduction through diuretic action. - Hypertension in patients who require an angiotensin receptor blocker combined with a thiazide diuretic: offers convenient dual therapy in a single tablet.

Adverse reactions may range from mild to severe and should be monitored during therapy.

Common Side Effects: - Dizziness or light‑headedness - Headache - Fatigue - Cough - Increased urination - Electrolyte disturbances (e.g., low potassium)

Serious or Rare Side Effects: - Severe hypotension - Acute kidney injury - Hyperkalemia - Angio‑edema - Liver function abnormalities - Severe skin reactions such as Stevens‑Johnson syndrome

Before starting therapy, clinicians should assess patient history and monitor relevant parameters. - Renal function: evaluate baseline creatinine and eGFR. - Electrolytes: check serum potassium and sodium levels. - Pregnancy: avoid use; drug is contraindicated in the second and third trimesters. - Concomitant NSAIDs: may reduce antihypertensive effect and increase renal risk. - Gout: monitor uric acid as thiazides can precipitate attacks. Store at below 25°C: keep in the original packaging, protect from moisture and direct sunlight.

Olmesartan Medoxil/Hydrochlorothiazide may interact with several drug classes; monitoring and dosage adjustments are often required.

Major Interactions (Avoid): - Aliskiren: combined use can cause excessive potassium elevation and renal impairment. - Potassium‑saving diuretics or supplements: risk of hyper‑kalemia. - Lithium: increased lithium levels may lead to toxicity.

Moderate Interactions (Monitor Closely): - NSAIDs: may blunt antihypertensive response and affect renal function. - ACE inhibitors or other ARBs: additive blood‑pressure lowering effect, risk of hypotension. - Antidiabetic drugs: may enhance hypoglycaemic effect. - CYP450 inhibitors: may modestly increase olmesartan concentrations.